MANTLE-CELL LYMPHOMA

This study looks at whether older adults with mantle cell lymphoma who achieve remission can safely stop taking zanubrutinib and restart it only if the cancer returns, instead of taking it every day indefinitely. The goal is to reduce side effects and costs without harming treatm…

This study tests a three-drug combination (ZGR) as the first treatment for people with mantle cell lymphoma who have not had any prior therapy. About 37 adults aged 18 to 80 will receive the drugs, and those at higher risk may also get CAR-T cell therapy followed by maintenance d…

This early-phase trial tests an oral drug called AS-1763 in adults with certain blood cancers (like CLL or lymphoma) that have not responded to at least two prior treatments. The main goals are to find the safest dose and see if the drug can shrink tumors. Around 120 participants…

This study tests whether adding the drug pirtobrutinib to a standard CAR T-cell therapy (brexu-cel) helps adults with mantle cell lymphoma that has returned or stopped responding to treatment. About 60 participants will be randomly assigned to receive pirtobrutinib either before …

This study offers ongoing access to the drug ibrutinib for people with certain blood cancers (like chronic lymphocytic leukemia or mantle cell lymphoma) who are already taking it and benefiting. Researchers will track side effects and disease changes over time. About 700 particip…

This study tests a faster way to increase the dose of sonrotoclax, a drug that blocks a protein helping cancer cells survive. It is given after initial treatment with zanubrutinib or rituximab. The trial includes 30 adults with chronic lymphocytic leukemia, small lymphocytic lymp…

This study tests a drug called pemigatinib in adults with certain types of B-cell non-Hodgkin lymphoma that have come back or not responded to at least two prior treatments. The goal is to see if the drug can shrink tumors or stop the cancer from growing. About 27 participants wi…

This early-phase study is testing an experimental oral drug called LP-168 in about 60 people with certain blood cancers (like CLL, lymphoma, and Waldenstrom macroglobulinemia) that have returned or not responded to prior therapies. The main goals are to find the safest dose and u…

This early-phase study tests a new drug called SGR-1505 in about 98 adults with various B-cell blood cancers (like lymphoma and leukemia). The main goals are to check safety and find the best dose. Participants will receive the drug and be monitored for side effects and how the d…

This study is for people with B-cell blood cancers like lymphoma and leukemia. It tests a new drug, BGB-16673, that breaks down a protein helping cancer grow. The goal is to find the right dose and see if it is safe and shrinks tumors. About 146 people in China will take part.

This early-phase study tests a new type of CAR T cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It is for people with non-Hodgkin lymphoma that has come back or not responded to standard treatments. The main goals are to check safety and find the right…

This study tests a new treatment for people with certain types of lymphoma or leukemia that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack cancer cells. The main g…

This study tests a combination of two drugs—glofitamab and ibrutinib—plus a pretreatment drug called obinutuzumab for people with mantle cell lymphoma (MCL). It includes patients aged 65 and older, or those 18-64 with high-risk features. The goal is to see if the combo is safe an…

This study tests a new treatment called CTX112 for people with B-cell blood cancers (like lymphoma or leukemia) that have come back or not responded to standard therapy. CTX112 uses CRISPR gene-editing to create donor T-cells that target and kill cancer cells. The trial involves …

This study is for people with certain blood cancers (like CLL or lymphoma) who are starting a type of drug called a BTK inhibitor. These drugs can raise blood pressure and increase the risk of heart problems. The study will test if carefully managing high blood pressure can lower…

This early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells. The main…

This early-phase study tests whether giving specially engineered immune cells (CAR T-cells) along with a vaccine can safely prevent B-cell lymphoma from coming back after a stem cell transplant. About 15 adults with aggressive or returning lymphoma will receive the treatment. The…

This study is for adults with mantle cell lymphoma, a type of blood cancer. Researchers are testing a combination of two drugs, zanubrutinib and tafasitamab, to find the safest and most effective dose. The goal is to see if the combination can shrink or eliminate tumors. About 27…

This early-stage study tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have returned or not improved with standard treatments. The therapy uses a harmless virus to deliver a gene that helps the immune system attack c…

This study is testing a new drug called AZD0486, either alone or with other cancer drugs, in people with certain types of blood cancers like leukemia and lymphoma. The goal is to see if the drug is safe and works against the cancer. About 408 adults will take part in this early-p…

This study tests whether a combination of three drugs—acalabrutinib, obinutuzumab, and glofitamab—is safe and effective for people with mantle cell lymphoma that has come back or stopped responding to prior treatments. About 40 adults will receive the drugs, which work by blockin…

This study tests a drug called acalabrutinib combined with standard chemotherapy (R-CHOP) in people with untreated mantle cell lymphoma, a rare blood cancer. About 55 adults in Spain who cannot have a stem cell transplant will receive the combination for 6 cycles, then continue a…

This study tests a new drug called rocbrutinib for people with mantle cell lymphoma (MCL) that has come back or stopped responding to treatment. About 394 adults will either receive rocbrutinib or one of the standard BTK inhibitor drugs. The goal is to see if rocbrutinib can keep…

This study tests a new drug combination (bendamustine, rituximab, cytarabine, and zanubrutinib) as initial treatment for mantle cell lymphoma. After this induction phase, participants receive maintenance therapy with zanubrutinib and rituximab, with or without an additional drug …

This study is for people with mantle cell lymphoma that has come back or not responded to prior treatment. It tests whether adding two oral medications (sonrotoclax and zanubrutinib) to standard CAR-T cell therapy can improve how well the cancer responds. About 40 adults will tak…

This early-phase study tests a new drug, ONM-501, injected directly into tumors, either alone or with another drug (cemiplimab), in people with advanced solid tumors or lymphomas that have not responded to other treatments. The main goals are to find the safest dose and understan…

This study tests a combination of two drugs, acalabrutinib and obinutuzumab, in people with untreated, slow-growing lymphomas like follicular lymphoma. The goal is to see if the combo can shrink tumors and control the disease. About 49 adults will take part, and researchers will …

This study is testing a combination of three drugs (acalabrutinib, venetoclax, and obinutuzumab) for people with mantle cell lymphoma, a type of blood cancer. It includes both patients whose cancer has come back or not responded to prior treatment, as well as those who have not y…

This study is for people with certain types of B-cell or Hodgkin lymphoma. Participants first get a stem cell transplant using their own cells, then receive a targeted drug called polatuzumab vedotin every 3 weeks for up to 8 doses. The goal is to see if this approach is safe and…

This early-phase study tests whether a personalized cell therapy (CAR-T cells) is safe for people with certain types of Non-Hodgkin lymphoma that have come back or not responded to standard treatments. Up to 36 participants will receive their own immune cells that have been genet…

This study tests an experimental drug called BGB-16673 in people with several types of B-cell cancers (like lymphoma and leukemia) that have come back or not responded to other treatments. The drug works by breaking down a protein (BTK) that helps these cancer cells grow. The tri…

This early-phase study tests whether it is safe and possible to collect a patient's own blood stem cells and give them together with CAR-T cell therapy for people with blood cancers that have come back or not responded to treatment. About 20 adults aged 18 to 85 with certain type…

This study tests whether combining two drugs—glofitamab and pirtobrutinib—can safely shrink tumors in adults with mantle cell lymphoma that returned or didn't respond to prior treatment. About 30 participants will receive the combination and be monitored for side effects and canc…

This early-phase trial tests a new treatment called CLIC-2201 for people with certain blood cancers (like lymphoma or leukemia) that have not responded to standard therapy or have returned. The treatment uses a patient's own immune cells, which are modified in a lab to better rec…

This study tests a stem cell transplant from a half-matched donor for people with blood cancers. Before the transplant, patients receive chemotherapy and low-dose radiation to prepare the body. The goal is to see if this approach helps the new stem cells grow and fight cancer wit…

This study tests a combination of three drugs (glofitamab, venetoclax, and lenalidomide) in people newly diagnosed with a fast-growing type of mantle cell lymphoma. The goal is to see if this mix is safe and works better than current treatments. About 50 adults aged 18 to 80 with…

This early-stage trial tests a new drug called IKS03 in people with advanced B-cell non-Hodgkin lymphoma that has not responded to other treatments. IKS03 is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The study aims to find the safest…

This early-phase study tests a new treatment for adults with B-cell blood cancers (like lymphoma) that have not responded to prior therapies. Participants receive a special type of immune cell (CAR T-cells) along with a targeted drug called pirtobrutinib, which is given before an…

This study tests a chemotherapy-free combination of two drugs, pirtobrutinib and rituximab, in 50 adults with newly diagnosed low or intermediate risk Mantle Cell Lymphoma. The goal is to see if this treatment can keep the cancer in long-term remission. Participants must not have…

This study tests a combination of two drugs, nemtabrutinib and rituximab, for people with untreated mantle cell lymphoma, a rare blood cancer. The goal is to see if this combo can kill more cancer cells. About 27 adults will take part in this phase 2 trial.

This study tests whether combining two drugs, pirtobrutinib and venetoclax, can help control mantle cell lymphoma (MCL) that has returned or not responded to prior therapy. About 30 adults with confirmed MCL will take both pills by mouth. The goal is to see how many patients' tum…

This study is for people with untreated mantle cell lymphoma, a type of blood cancer. It tests whether adding an experimental drug called venetoclax to two standard drugs (lenalidomide and rituximab) is safe and works well. About 28 adults will take part to find the best dose and…

This study tests whether adding a third drug (cytarabine) to the standard two-drug chemo regimen can help older adults with mantle cell lymphoma live longer without their cancer growing. The trial enrolls 90 patients aged 70+ (or 60+ if not eligible for transplant) who have not y…

This study offers a CAR T-cell therapy called brexucabtagene autoleucel to people with mantle cell lymphoma or acute lymphoblastic leukemia whose commercially made treatment batch didn't pass quality checks. Participants must have a batch that still meets the study's safety stand…

This study tests whether adding sonrotoclax to the standard drug zanubrutinib helps adults with mantle cell lymphoma that has returned or stopped responding to prior treatments. About 300 participants will receive either the combination or a placebo plus zanubrutinib. The main go…

This study tests a new type of PET/CT scan that looks for a protein called CD70 on cancer cells. It aims to better detect kidney cancer, lymphoma, and nasopharyngeal cancer in 300 adults. The scan may help doctors see tumors more clearly and guide treatment decisions.

This study tests whether giving cancer treatment at home is preferred over going to a clinic. It involves 27 adults with various cancers in the Florida Panhandle. The goal is to see if home care improves patient satisfaction and is safe.

This study is testing whether an artificial intelligence tool can help match cancer patients to clinical trials they might be eligible for. Researchers will enroll up to 50,000 people with various types of cancer and use the AI to suggest trials. The goal is to see if this approa…

This study watches how BTK inhibitors, a type of leukemia treatment, affect the heart's rhythm. About 135 adults with certain blood cancers who are taking or about to start these drugs will have heart tests like EKGs, stress tests, and heart imaging. The goal is to spot dangerous…

This study is testing whether a new machine that combines radiation therapy with real-time MRI imaging is safe and practical for treating several types of cancer, including stomach and breast cancer. About 70 adults will receive this treatment along with chemotherapy. The goal is…

This study looks at whether CAR-T cell therapy, a treatment for certain blood cancers, reduces the protection that past vaccines (like measles or tetanus shots) provide. Researchers will test the blood of 45 adults with multiple myeloma or non-Hodgkin lymphoma before and after CA…

This study looks at how the immune system of people with lymphoma responds to flu and COVID vaccines. Researchers will measure antibody levels and immune cells in 200 participants with different types of lymphoma and compare them to healthy individuals. The goal is to understand …

This study follows up to 500 people who received CAR-T cell therapy for blood cancers like leukemia, lymphoma, or multiple myeloma. Researchers will track participants for up to 15 years to see if any new cancers develop. The goal is to understand the long-term safety of this tre…